Here is a near irrefutable conclusion: QCOR executive management is planning for significant and sustainable growth.
1. Growing their sales force aggressively.
2. More than doubling their research budget, 2012 compared to 2011.
3. Retooling and expanding their reimbursement team at considerable expense.
4. Adding key and experienced executives in business development and sales management.
They have fundamental and historical reason to believe ROI for these initiatives will follow:
--vials shipped up 94% YOY;
--EPS up 160% YOY;
--net sales up 133% YOY.
Does this sound like a company on the defensive?
Getting overly distracted by short seller and market manipulations?
Fearful of reimbursement issues?
In a word: no.
QCOR is on a sustainable roll.
This company is flat out performing.
Let's keep this in mind and stay rational, keep a sense of humor amid all the noise and clamor and volatility.
Noise that sometimes gets loud enough to drive irrational action on the part of some investors, which is precisely the intent.
Stay the course.
Questcor is stronger than ever, by every measure, and that's really all we need to know.
Sentiment: Strong Buy
I agree with your fundamental analysis. But we can not ignore the fact that its has very short interest and shorties will do anything ( roumors, fake lawsuites etc. ) to bring the price down.
its been 6 months since the BIG drop.. its about time we start going back to 50s. i think 2nd Q numbers should do it.. .. by the time 3rd Q reports oh say 200m+ with 1.50 is really when we'll see the short's thesis debunked once and for all and climb to triple digits.
i have time and this is a gold find. show me any other stock w/ QCOR kind of fundamentals and growth and i'll be all over that one.. so far i haven't seen one yet.
Agreed--QCOR requires patience, but ya know, with a forward P/E of something like 6.5? I have patience same as you.
What never gets mentioned"
Along with the steady growth, we get a handful of lottery tickets:
--How about news of a new indication application? Take your pick. Several great candidates.
--How about news of an acquisition offer?
--How about news of a successful trial where Acthar delays onset of ALS or mitigates symptoms?
--What if rheumatology scripts explode in Q2--past what I've been projecting?
Any of these are possible, and any of these is a game changer.
Would I bet the store any of these will happen? No...but nice to have them out there.
Sentiment: Strong Buy